dalfampridine — United Healthcare
multiple sclerosis
Initial criteria
- Diagnosis of multiple sclerosis
- AND Physician confirmation that patient has difficulty walking (e.g., Timed 25-foot Walk)
Reauthorization criteria
- Physician confirmation that the patient’s walking improved with Ampyra therapy
Approval duration
12 months